Most cited papers from Pfizer (United States)

Pfizer (United States)

What are the most cited papers from Pfizer (United States)?

The most cited paper from Pfizer (United States) is "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1" (Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy et al., 2001), with 18,154 citations. Next come "An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest" (14,405) and "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings" (11,492).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 2,275 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1 Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy et al. · Advanced Drug Delivery Reviews Review	Mar 2001	18,154
2	An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest Rahul S. Desikan, Florent Ségonne, Bruce R. Fischl et al. · NeuroImage	14 Mar 2006	14,405
3	Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy et al. · Advanced Drug Delivery Reviews Review	1997	11,492
4	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative Daniel Aletaha et al. · Arthritis & Rheumatism Open access	10 Aug 2010	9,731
5	Biological insights from 108 schizophrenia-associated genetic loci Stephan Ripke et al. · Nature Open access297 authors	Jul 2014	8,181
6	Lead- and drug-like compounds: the rule-of-five revolution Christopher A. Lipinski · Drug Discovery Today Technologies	Dec 2004	6,290
7	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy Open access2,467 authors	2 Jan 2016	6,023
8	Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure Michael R. Bristow, Leslie Ann Saxon, JOHN P. BOEHMER et al. · New England Journal of Medicine	19 May 2004	5,848
9	Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale John T. Farrar, James P. Young, Linda LaMoreaux et al. · Pain	Nov 2001	5,825
10	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Robert John Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine Open access	10 Jan 2007	5,801
11	Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation Diane J. Wild, Alyson Grove, Mona L. Martin et al. · Value in Health Open access	Mar 2005	5,609
12	Proposed minimum reporting standards for chemical analysis Lloyd W. Sumner et al. · Metabolomics Open access	11 Sep 2007	5,359
13	The biology and management of non-small cell lung cancer Roy S. Herbst, Daniel Morgensztern, CHRIS H. BOSHOFF · Nature	2018	5,116
14	Genetic effects on gene expression across human tissues François Aguet et al. · Nature Open access250 authors	10 Oct 2017	4,762
15	Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Eunice Lee Kwak et al. · New England Journal of Medicine Open access	27 Oct 2010	4,517
16	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science	26 Apr 2007	4,504
17	FinnGen provides genetic insights from a well-phenotyped isolated population Mitja Kurki et al. · Nature Open access169 authors	18 Jan 2023	4,362
18	Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Takeshi Nishikawa, Diane Edelstein, Xue Liang Du et al. · Nature	Apr 2000	4,302
19	Core outcome measures for chronic pain clinical trials: IMMPACT recommendations Robert H. Dworkin et al. · Pain	6 Nov 2004	3,789
20	Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics Fariborz Mohamadi, Nigel G. J. Richards, Wayne C. Guida et al. · Journal of Computational Chemistry	May 1990	3,774
21	Drug-like properties and the causes of poor solubility and poor permeability Christopher A. Lipinski · Journal of Pharmacological and Toxicological Methods	Jul 2000	3,766
22	Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Lecia Van Dam Sequist et al. · Science Translational Medicine Open access	23 Mar 2011	3,603
23	How many drug targets are there? John P. Overington, Bissan Al‐Lazikani, Andrew L. Hopkins · Nature Reviews Drug Discovery Review	Dec 2006	3,554
24	Core outcome domains for chronic pain clinical trials: IMMPACT recommendations Dennis C. Turk et al. · Pain	22 Sep 2003	3,518
25	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease John C. LaRosa, Scott M. Grundy, David D. Waters et al. · New England Journal of Medicine Open access	9 Mar 2005	3,517
26	Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations Robert H. Dworkin et al. · Journal of Pain Open access	13 Dec 2007	3,496
27	Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine Open access	Jun 2013	3,429
28	Membrane transporters in drug development Kathleen M. Giacomini et al. · Nature Reviews Drug Discovery ReviewOpen access	Mar 2010	3,373
29	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression eQTLGen et al. · Nature Genetics Open access218 authors	26 Apr 2018	3,347
30	The druggable genome Andrew L. Hopkins, Colin R. Groom · Nature Reviews Drug Discovery	Sep 2002	3,335
31	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis Raoul Herbrecht et al. · New England Journal of Medicine Open access	8 Aug 2002	3,326
32	Applications of machine learning in drug discovery and development Jessica J. Vamathevan, Dominic A. Clark, Paul Czodrowski et al. · Nature Reviews Drug Discovery ReviewOpen access	11 Apr 2019	3,274
33	A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes Philipp E. Scherer, Suzanne P. Williams, Michael Fogliano et al. · Journal of Biological Chemistry Open access	Nov 1995	3,253
34	First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer Benjamin J. Solomon, Tony S.K. Mok, Dong‐Wan Kim et al. · New England Journal of Medicine Open access	3 Dec 2014	3,251
35	Effects of Torcetrapib in Patients at High Risk for Coronary Events Philip J. Barter, Mark J. Caulfield, Mats A. L. Eriksson et al. · New England Journal of Medicine Open access	5 Nov 2007	3,168
36	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms Faiez M. Zannad, John J.V. McMurray, Henry Krum et al. · New England Journal of Medicine Open access	14 Nov 2010	3,112
37	Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction RC Rosen, JC Cappelleri, MD Smith et al. · International Journal of Impotence Research	Dec 1999	3,073
38	Palbociclib and Letrozole in Advanced Breast Cancer Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine	16 Nov 2016	3,059
39	Mapping genomic loci implicates genes and synaptic biology in schizophrenia Vassily Vladimirovich Trubetskoy et al. · Nature Open access613 authors	8 Apr 2022	2,894
40	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy Matthew J. Maurer et al. · New England Journal of Medicine Open access	27 Aug 2018	2,841
41	The PI3K Pathway in Human Disease David A. Fruman, Honyin Chiu, Benjamin David Hopkins et al. · Cell Open access	Aug 2017	2,806
42	Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) Didier Bouhassira, Nadine Attal, H. Alchaar et al. · Pain	29 Jan 2005	2,755
43	Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 Daniel J. Klionsky et al. · Autophagy Open access2,930 authors	2 Jan 2021	2,743
44	A synthetic inhibitor of the mitogen-activated protein kinase cascade. David T. Dudley, Long Pang, Stuart J. Decker et al. · Proceedings of the National Academy of Sciences Open access	15 Aug 1995	2,717
45	From Vulnerable Plaque to Vulnerable Patient Morteza Naghavi et al. · Circulation	13 Oct 2003	2,670
46	Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study Debra E. Irwin, Ian Milsom, Steinar Hunskaar et al. · European Urology	3 Oct 2006	2,647
47	Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis Christoph Wanner, Vera Krane, Winfried März et al. · New England Journal of Medicine Open access	20 Jul 2005	2,634
48	AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC Veit Hornung, Andrea Ablasser, Marie Charrel-Dennis et al. · Nature Open access	21 Jan 2009	2,632
49	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett et al. · The Lancet	Oct 2006	2,626
50	New insights into the genetic etiology of Alzheimer’s disease and related dementias Céline Bellenguez et al. · Nature Genetics Open access1,266 authors	Apr 2022	2,608

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.